Livial is an oral HRT preparation that has recently had some good news researchers have given it the thumbs up as a preventative of postmeno pausal osteoporosis. It is a study that the manufacturer, Organon Laboratories, has long been waiting on, and it places the drug on more of an even footing with other HRT rivals.
Although the drug is not yet licensed for use in the US, the new British Journal of Obstetrics and Gynaecology (1998; 105: 904-11) study may quicken the day.
The drug is supposed to be taken by postmenopausal women who are suffering from hot flushes and sweating, depression and decreased libido and, now, those who are at risk of suffering a fracture.
Women are warned not to take the drug until 12 months after their last menstrual bleed as it can interfere with the regular cycle, while those who are switching from another HRT preparation are advised to first take a progestogen to induce a withdrawal bleed first.
Doctors should think twice about prescribing the drug if the patient has a history of liver or kidney disease, epilepsy or migraine.
Treatment should be stopped if there are signs of thromboembolism (blockage of a blood vessel), if liver tests show an abnormality or if jaundice is detected.
Women who are on anticoagulants also need to be monitored carefully, especially if they are already sensitive to them, because Livial can interact with them.
If you survive all those hurdles, typical adverse reactions include a change in body weight, dizziness, rash, pruritus, vaginal bleeding, headache, migraine, depression, blurred vision, gastrointestinal upsets, increased facial hair and musculoskeletal pain. So you could be menopausal or you could just be a Livial patient.